suprefact injektioneste
sanofi-aventis oy - buserelini acetas - injektioneste - busereliini
suprefact 0.1 mg/annos nenäsumute
sanofi-aventis oy - buserelini acetas - nenäsumute - 0.1 mg/annos - busereliini
suprefact depot 6.3 mg implantaatti
sanofi-aventis oy - buserelini acetas - implantaatti - 6.3 mg - busereliini
suprefact depot 9.45 mg implantaatti
sanofi oy - buserelini acetas - implantaatti - 9.45 mg - busereliini
prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics
novartis vaccines and diagnostics s.r.l. - influenssa virus pinta-antigeenejä (haemagglutinin ja neuraminidaasin) kanta a, vietnam, 1194, 2004 (h5n1) - influenza, human; immunization; disease outbreaks - rokotteet - aktiivinen immunisaatio influenssa a -viruksen h5n1-alatyypin suhteen. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.
buprefarm 5 mikrog/tunti depotlaastari
orifarm generics a/s - buprenorphine - depotlaastari - 5 mikrog/tunti - buprenorfiini
buprefarm 10 mikrog/tunti depotlaastari
orifarm generics a/s - buprenorphine - depotlaastari - 10 mikrog/tunti - buprenorfiini
buprefarm 20 mikrog/tunti depotlaastari
orifarm generics a/s - buprenorphine - depotlaastari - 20 mikrog/tunti - buprenorfiini
buprefarm 15 mikrog/tunti depotlaastari
orifarm generics a/s - buprenorphine - depotlaastari - 15 mikrog/tunti - buprenorfiini
buprefarm 25 mikrog/tunti depotlaastari
orifarm generics a/s - buprenorphine - depotlaastari - 25 mikrog/tunti - buprenorfiini